Skip to main content
. 2019 Feb 5;27(2):269–279. doi: 10.3727/096504018X15215019227688

Figure 3.

Figure 3

Effect of miR-615-3p on A549 cell tumor growth and metastasis in vivo. (A) A549 cells were transfected with miR-NC or miR-615-3p and then were implanted into the nude mice. The tumor volume was measured every 3 days. The tumors of the two groups were separated at the end of treatment. (B) The tumors were removed and embedded in paraffin for immunohistochemical staining with Ki-67. (C) Metastatic lesions in the lungs of the NSCLC cell metastasis models are shown at 6 weeks after tail vein injection. The total number of lung metastatic lesions in the miR-615-3p transfection groups was much less than those in controls. (D) A549 cells were transfected with miR-NC inhibitor or miR-615-3p inhibitor and then were implanted into the nude mice. The tumor volume was measured every 3 days. (E) The tumors were removed and embedded in paraffin for immunohistochemical staining with Ki-67. (F) Metastatic lesions in the lungs of the models are shown at 6 weeks after tail vein injection. The total number of lung metastatic lesions in the miR-615-3p downregulated group was much higher than those in controls. **p < 0.01, compared to miR-NC inhibitor.